PRO DRUGS OF PDE10 COMPOUNDS

The present invention is directed to pro drugs of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-amine which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiestera...

Full description

Saved in:
Bibliographic Details
Main Authors Mittal, Sachin, Skudlarek, Jason W, Raheem, Izzat T
Format Patent
LanguageEnglish
Published 29.09.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The present invention is directed to pro drugs of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-amine which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
AbstractList The present invention is directed to pro drugs of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-amine which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Author Mittal, Sachin
Skudlarek, Jason W
Raheem, Izzat T
Author_xml – fullname: Mittal, Sachin
– fullname: Skudlarek, Jason W
– fullname: Raheem, Izzat T
BookMark eNrjYmDJy89L5WSQCQjyV3AJCnUPVvB3UwhwcTU0UHD29w3wD_VzCeZhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfGhwUYGRkbGBmZmhpaOhsbEqQIAsScjMA
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID US2022306619A1
GroupedDBID EVB
ID FETCH-epo_espacenet_US2022306619A13
IEDL.DBID EVB
IngestDate Fri Jul 19 12:48:56 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_US2022306619A13
Notes Application Number: US202217695125
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220929&DB=EPODOC&CC=US&NR=2022306619A1
ParticipantIDs epo_espacenet_US2022306619A1
PublicationCentury 2000
PublicationDate 20220929
PublicationDateYYYYMMDD 2022-09-29
PublicationDate_xml – month: 09
  year: 2022
  text: 20220929
  day: 29
PublicationDecade 2020
PublicationYear 2022
RelatedCompanies Merck Sharp & Dohme Corp
RelatedCompanies_xml – name: Merck Sharp & Dohme Corp
Score 3.422478
Snippet The present invention is directed to pro drugs of...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Title PRO DRUGS OF PDE10 COMPOUNDS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220929&DB=EPODOC&locale=&CC=US&NR=2022306619A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS8MwFD6MKeqbTsVLlYLSt2LXy2weirikdQi90K6yt9E1KQgyh6v49z0Jne5pLyEXOLnAycmXnPMF4F5SjCwazk3HqhvTdR1h-k7NTc_DdGT5jT2UwclxMpqU7uvMm_XgYxMLo3hCfxQ5ImpUjfreqv169X-JxZRv5fph8Y5Vn0_RNGBGh45t20Jzb7BxEGYpS6lBaVAWRpKrNjwdI1x4Rqy0Jw_Skmk_fBvLuJTVtlGJjmE_Q3nL9gR6YjmAQ7r5e20AB3H35I3ZTvvWp6BleaqzvHwp9DTSMxYOLZ2mcZaWCSvO4C4Kp3RiYjfzv1nNy2J7TM459BHviwvQxWPDETf63K0ql_CKSBYtQgRBcENq4V-CtkvS1e7maziSRenyYBMN-u3Xt7hBu9oubtVy_ALhp3dT
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFOebTsVp1YLSt2LXj615GOKa1arrB-sqeyttk4Igc7iK_76X0ume9hJCDi4fcLn8krtfAO4ExUheMqYaWlGqpmlw1TYKploWlgPNLvW-SE72g4GXmC8La9GCj00uTM0T-lOTI6JFFWjvVb1fr_4vsWgdW7m-z9-x6fPBnY-o0qBjXdfQ3St0PJpEIQ0dxXFGSawEs1qGp2OEC4-IlfaGgp9XHJ7exiIvZbXtVNwj2I9Q37I6hhZfdqHjbP5e68KB3zx5Y7WxvvUJSNEslOkseYrl0JUjOulrshP6UZgEND6FW3cydzwVu0n_ZpUm8faYjDNoI97n5yDzYckQN9rMzDKTsIwIFi1COEFwQwpu90Dapelit_gGOt7cn6bT5-D1Eg6FSIQ_6ESCdvX1za_Qx1b5db00v52vekA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=PRO+DRUGS+OF+PDE10+COMPOUNDS&rft.inventor=Mittal%2C+Sachin&rft.inventor=Skudlarek%2C+Jason+W&rft.inventor=Raheem%2C+Izzat+T&rft.date=2022-09-29&rft.externalDBID=A1&rft.externalDocID=US2022306619A1